Skip to content

Clinical Observation of Yiqi Joint Venture Traditional Chinese Medicine Combined with Precise Minimally Invasive Debridement in the Treatment of Granulomatous Lobular Mastitis

Study on the Clinical Efficacy and Standardized Scheme of Hormone Therapy for Granulomatous Mastitis

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100050368
Enrollment
Unknown
Registered
2021-08-26
Start date
2021-09-01
Completion date
Unknown
Last updated
2022-04-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Granulomatous lobular mastitis

Interventions

Sponsors

The Affiliated Hospital of Shandong University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1. Non pregnant and lactating female patients; 2. The pathological diagnosis was granulomatous mastitis in the stage of mass or abscess; 3. Female patients over 18 years old (including 18 years old) and under 50 years old; 4. Volunteer to participate in the trial and sign the informed consent; 5. Be able to cooperate with researchers to complete the investigation.

Exclusion criteria

Exclusion criteria: 1. TB infected T cells (ESAT-6, CFP-10), PDD tuberculin test suspected breast tuberculosis patients; 2. Unable to take hormone due to physical or other reasons; 3. Patients with other immune related diseases; 4. Patients with severe primary diseases such as cardiovascular, cerebrovascular, kidney, liver, endocrine system and hematopoietic system, mental patients, or mental or legal disabilities; 5. According to the judgment of the researchers, other diseases that reduce the possibility of enrollment or complicate the enrollment, such as frequent changes in the working environment, are likely to cause loss of follow-up, and those who cannot give full informed consent due to mental and behavioral disorders.

Design outcomes

Primary

MeasureTime frame
Breast symptoms;Ultrasound imaging of breast;laboratory examination;The effective rate of conservative treatment;Operation method;The aesthetic degree of breast appearance;Duration of disease;Recurrence rate;Patient satisfaction after cure;

Countries

China

Contacts

Public ContactLiu Xiaofei

The Affiliated Hospital of Shandong University of Traditional Chinese Medicine

drliuxf@126.com+86 15615611377

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026